Cancer · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in cancer measured by clinical assessment over 28 months compared with placebo (low certainty).
1 finding from 1 review
Mortality measured by clinical assessment over 12 months · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in mortality measured by clinical assessment over 28 months compared with placebo (low certainty).
1 finding from 1 review
Clinical relapse · relapsing multiple sclerosis
Rituximab as 'switching' may leads to lower relapse measured by clinical assessment over 12 months compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events measured by clinical assessment over 12 months · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes serious adverse events measured by clinical assessment over 12 months compared with placebo (very low certainty).
1 finding from 1 review
Common infections measured by clinical assessment over 12 months · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes common infections measured by clinical assessment over 12 months compared with placebo (very low certainty).
1 finding from 1 review
Cancer · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes cancer measured by clinical assessment over 12 months compared with placebo (very low certainty).
1 finding from 1 review
Mortality measured by clinical assessment over 12 months · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes mortality measured by clinical assessment over 12 months compared with placebo (very low certainty).
1 finding from 1 review
Clinical relapse · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in relapse measured by clinical assessment over 24 months compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events measured by clinical assessment over 12 months · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in serious adverse events measured by clinical assessment over 28 months compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Initiation of white spot lesions (WSL), visual-tactile assessment
The intervention showed no clear difference in initiation of white spot lesions (WSL), visual-tactile assessment; GRADE not reported.
1 finding from 1 review
RR 1.02 [0.82, 1.27]
Studies not reported
GRADE not reported
Intervention not reported
Initiation of white spot lesions (WSL), visual-tactile assessment
The intervention showed no clear difference in initiation of white spot lesions (WSL), visual-tactile assessment; GRADE not reported.
1 finding from 1 review
RR 0.82 [0.66, 1.02]
Studies not reported
GRADE not reported
Intervention not reported
Initiation of white spot lesions (WSL), visual-tactile assessment
The intervention showed no clear difference in initiation of white spot lesions (WSL), visual-tactile assessment; GRADE not reported.
1 finding from 1 review
RR 0.85 [0.66, 1.10]
Studies not reported
GRADE not reported
Initiation of white spot lesions (WSL), visual-tactile assessment · Patients of any age (11-40 years) receiving comprehensive/fixed orthodontic treatment with fixed appliances
For resin-based sealants, fluoride release did not significantly change WSL initiation (RR 0.71, wide CI); subgroup not separately GRADE-rated.
1 finding from 1 review
Initiation of white spot lesions (WSL), visual-tactile assessment · Patients of any age (11-40 years) receiving comprehensive/fixed orthodontic treatment with fixed appliances
The additional use of a sealant probably reduces the initiation of white spot lesions during fixed orthodontic treatment compared with no sealant (RR 0.70), but the certainty of evidence is very low.
1 finding from 1 review
Intervention not reported
Initiation of white spot lesions (WSL), visual-tactile assessment
The intervention showed no clear difference in initiation of white spot lesions (WSL), visual-tactile assessment; GRADE not reported.
1 finding from 1 review
RR 0.83 [0.67, 1.04]
Studies not reported
GRADE not reported
Initiation of white spot lesions (WSL), visual-tactile assessment · Patients of any age (11-40 years) receiving comprehensive/fixed orthodontic treatment with fixed appliances
Fluoride-releasing coating materials do not appear to reduce WSL initiation more than non-fluoride coatings (RR 0.84, not significant); certainty of evidence is very low.
1 finding from 1 review
Initiation of white spot lesions (WSL), visual-tactile assessment · Patients of any age (11-40 years) receiving comprehensive/fixed orthodontic treatment with fixed appliances
For resin-based bonding agents, fluoride release did not significantly change WSL initiation (RR 0.97); subgroup not separately GRADE-rated.
1 finding from 1 review
Self- or observational assessment of intraoperative distress/pain/acceptance of treatment during provision of LA: pain-related behaviour (any disruptive behaviour/sudden reaction/movement) · Children and adolescents having dental treatment under local anaesthetic without general anaesthesia
1 finding from 1 review
pain-related behaviour (any disruptive behaviour/sudden reaction/movement); 4 studies reported a benefit in using the wand while the remaining studies results suggested no difference between the 2 methods of delivering…
6 studies · 704 participants
Very low
Self- or observational assessment of intraoperative distress/pain/acceptance of treatment during provision of LA: anxiety/pain experience (VAS, higher scores indicate worsened anxiety) · Children and adolescents having dental treatment under local anaesthetic without general anaesthesia
Video modelling acclimatisation for LA may leads to lower self- or observational assessment of intraoperative… compared with oral hygiene video (low certainty).
1 finding from 1 review
Self- or observational assessment of intraoperative distress/pain/acceptance of treatment during provision of LA (SEM scale, distress) · Children and adolescents having dental treatment under local anaesthetic without general anaesthesia
1 finding from 1 review
No numeric data reported. Study authors reported lower distress values (SEM scale) for all categories in the combined counter-stimulation and distraction group; this difference was significant when compared to the…
1 study · 78 participants
Very low